July 25, 2016 2:27 AM ET

Biotechnology

Company Overview of Nivalis Therapeutics, Inc.

Key Executives for Nivalis Therapeutics, Inc.

NameBoard RelationshipsTitleAge
Jon Congleton 12 RelationshipsChief Executive Officer, President and Director53
R. Michael Carruthers 14 RelationshipsChief Financial Officer and Secretary58
Janice M. Troha No RelationshipsChief Operating Officer and Executive Vice President58
David M. Rodman M.D.No RelationshipsChief Medical Officer and Executive Vice President of Discovery--

Nivalis Therapeutics, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Howard P. Furst M.D. 17 RelationshipsDeerfield Management Company, L.P.49
Jon Congleton 12 RelationshipsNivalis Therapeutics, Inc.53
John R. Moore 12 RelationshipsArray BioPharma Inc.52
Robert E. Conway CPA 148 RelationshipsARCA biopharma, Inc.62
Michael A. Marletta Ph.D., M.D. 34 RelationshipsThe Scripps Research Institute65
View All Board Members

Nivalis Therapeutics, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee CPARobert E. Conway148 Relationships3 Executives
Compensation Committee John R. Moore12 Relationships2 Executives
Nominating Committee M.D.Howard P. Furst17 Relationships2 Executives
Corporate Governance Committee M.D.Howard P. Furst17 Relationships2 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary$375.0K
375.0K
381.0K
Bonus
Not meaningful
Total Short Term Compensation
Not meaningful
Total Value of Options$375.0K
375.0K
34.2M
Compensation as of Fiscal Year 2015
Nivalis Therapeutics, Inc. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

Cleveland BioLabs, Inc. Announces Executive Changes
July 22, 2016 8:22 PM ET
TetraLogic Pharmaceuticals Corporation Announces Resignation of Douglas Reed as M. D, Effective July 21, 2016
July 22, 2016 8:18 PM ET
ContraFect Corporation Appoints Steven C. Gilman as President and Chief Executive Officer
July 21, 2016 9:32 PM ET
William R. Ringo Intends to Resign from Mirati Therapeutics, Inc.'s Board of Directors
July 21, 2016 8:03 PM ET
Biostage Appoints Harout Dersimonian as Chief Scientific Officer to Oversee Cell Biology, Materials Science and Other Research Underlying its Organ Implant Development
July 21, 2016 12:56 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Nivalis Therapeutics, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.